Skip to main content
Hauptrubriken
CME Facharzt-Training Webinare Zeitschriften Bücher e.Medpedia Podcast
Service
Jobbörse Info & Hilfe
Fachgebiete
Anästhesiologie Allgemeinmedizin Arbeitsmedizin Augenheilkunde Chirurgie Dermatologie Gynäkologie und Geburtshilfe HNO Innere Medizin Kardiologie Neurologie Onkologie und Hämatologie Orthopädie und Unfallchirurgie Pädiatrie Pathologie Psychiatrie Radiologie Rechtsmedizin Urologie Zahnmedizin
Themen
Klimawandel und Gesundheit Neues aus dem Markt COVID-19 Praxis und Beruf Seltene Erkrankungen GOÄ & EBM Panorama
Sammlungen
Kasuistiken Algorithmen & Infografiken Blickdiagnosen Arthropedia FlapFinder (für Dermatochirurgen) Videos Kongressberichterstattung Medizin für Apothekerinnen und Apotheker Für Ärztinnen und Ärzte in Weiterbildung Für Medizinstudierende

Live-Webinar: Aktuelle Leitlinien bei Herz-Kreislauf-Erkrankungen

Konkret geht es um den Diabetes-Patienten mit kardiovaskulären Erkrankungen oder Risiken, die Herzinsuffizienz sowie die kardiovaskuläre Primär- und Sekundärprävention. Sind Sie hier schon auf dem neuesten Stand? Unsere Experten beleuchten, wo und warum das bisherige Procedere geändert werden soll und was in der Praxis sinnvoll ist. Holen Sie sich Ihr Update und 2 CME-Punkte beim MMW-Webinar am 24. April von 17.30 bis 19 Uhr. 
Erweiterte Suche
Anmelden
nach oben
Langenbeck's Archives of Surgery
Erschienen in: Langenbeck's Archives of Surgery 5/2012

01.06.2012 | Review Article

The role of HBIg as hepatitis B reinfection prophylaxis following liver transplantation

verfasst von: Arianeb Mehrabi, Majid Esmaeilzadeh, Hamidreza Fonouni, Mohammadreza Hafezi, Nuh N. Rahbari, Mohammad Golriz, Ali Majlesara, Morva Tahmasbi Rad, Mahmoud Sadeghi, Jan Schmidt, Tom M. Ganten

Erschienen in: Langenbeck's Archives of Surgery | Ausgabe 5/2012

Einloggen, um Zugang zu erhalten

Abstract

Background and introduction

Without adequate prophylaxis, liver transplantation (LTx) is frequently followed by hepatitis B virus (HBV) reinfection, which results in rapidly progressing liver disease and significantly decreased overall survival. In the last two decades, significant progress has been made in the prophylaxis and treatment of HBV.

Discussion

We present an overview of different protocols and regimens used for prophylaxis of HBV reinfection after LTx and describe the protocol implemented at our center. Following LTx, HBV reinfection can be effectively prevented by administration of anti-hepatitis B immunoglobulin (HBIg) alone or more recently in combination with antiviral nucleoside/nucleotide analogs (NUCs). Several studies reported good results with the use of HBIg alone, but combination treatment with HBIg and NUCs has proven to be a superior prophylactic regimen for HBV recurrence. At present, combination therapy (HBIg and a nucleoside or nucleotide analog) is the gold standard used in many transplantation centers. This preventive regimen reduces the risk of a recurrence of HBV infection and thereby the need for re-transplantation. Future and ongoing studies will show how long HBIg must be given after transplantation, especially when used in combination with potent antivirals, such as entecavir or tenofovir.
Literatur
1.
Alter MJ (2003) Epidemiology and prevention of hepatitis B. Semin Liver Dis 23:39–46PubMed
2.
Perz JF, Farrington LA, Pecoraro C, et al. Estimated global prevalence of hepatitis C virus infection [abstract]. In: Abstracts of the Infectious Diseases Society of America 42nd Annual Meeting, Boston, MA, September 2004.
3.
4.
Viral hepatitis guidelines in hemodialysis and transplantation. Am J Transplant 2004;4(10):72–82
5.
Colombo M, Sangiovani A (2003) Etiology, natural history and treatment of hepatocellular carcinoma. Antivir Res 60:145–150PubMed
6.
Ben Ari Z, Tur-Kaspa R (1997) New trends in liver transplantation for viral hepatitis. Am J Gastroenterol 92:2155PubMed
7.
Dodson SF, Issa S, Bonham A (1999) Liver transplantation for chronic viral hepatitis. Surg Clin North Am 79:131PubMed
8.
Rosen HR (2001) Hepatitis B and C in the liver transplant recipient: current understanding and treatment. Liver Transplant 7:S87–S98
9.
Faust D, Rabenau HF, Allwin R et al (2003) Cost-effective and safe ambulatory long term immunoprophylaxis with intramuscular instead f intravenous hepatitis B immunoglobulin to prevent reinfection after orthotopic liver transplantation. Clin Transplant 17:254–258PubMed
10.
Samuel D (2009) The option of liver transplantation for hepatitis B: where are we? Dig Liver Dis 41(suppl 2):S185–S189PubMed
11.
Coffin CS, Terrault NA (2007) Management of hepatitis B in liver transplant recipients. J Viral Hepatitis 14(suppl 1):37–44
12.
Pan T, Tang L, Yuan J et al (2007) Recombinant anti-HBsAg fab blocks hepatitis B virus infection after orthotopic liver transplantation. Hepatobilliary Pancreat Dis Int 6:370–375
13.
Buti M, Antonio M, Prieto M et al (2003) A randomized study comparing lamivudine monotherapy after a short course of hepatitis B immune globulin and lamivudine with long term lamivudine plus HBIg in the prevention of hepatitis B virus recurrence after liver transplantation. J Hepatol 38:811–817PubMed
14.
Neumann UP, Langrehr JM, Naumann U et al (2002) Impact of HLA compatibilities in patients undergoing liver transplantation for HBV cirrhosis. Clin Transplant 16:122–129PubMed
15.
Franics MJ, Kane M. Hepatitis B Vaccine, Chapter 10 in Vaccines, 3rd ed. Stanley A. Plotnick and Walter A. Orenstein, eds. W.B. Saunders Company; Philadelphia, 1999 (159–82).
16.
Engler SH, Sauer PW, Golling M et al (2001) Immunogenicity of two accelerated hepatitis B vaccination protocols in liver transplant candidates. Eur J Gastroenterol Hepatol 13:363–367PubMed
17.
Eisenbach C, Sauer P, Mehrabi A et al (2006) Prevention of hepatitis B virus recurrence after liver transplantation. Clin Transplant 20(suppl 17):111–116PubMed
18.
Riediger C, Berberat PO, Sauer P et al (2007) Prophylaxis and treatment of recurrent viral hepatitis after liver transplantation. Nephrol Dial Transplant 22(Suppl 8):viii37–viii46PubMed
19.
Wang ZX, Ding GS, Fu H et al (2004) Prevention of hepatitis B virus reinfection after orthotopic liver transplantation. Hepatobiliary Pancreat Dis Int 3:345–348PubMed
20.
Wang ZF, Liu C (2004) Liver retransplantation: indication and outcome. Hepatobiliary Pancreat Dis Int 3:175–178PubMed
21.
Zhu JP, Zhang TL, Li L et al (2003) Prevention and treatment of hepatitis B recurrence after liver transplantation. Hepatobiliary Pancreat Dis Int 2:500–503PubMed
22.
Terrault NA, Zhou S, Combs C et al (1996) Prophylaxis in liver transplant recipients using a fixed dosing schedule of hepatitis B immunoglobulin. Hepatology 24:1327–1333PubMed
23.
Zheng SS, Wu J, Liang TB et al (2002) Prophylaxis and treatment of hepatitis B virus reinfection following liver transplantation. Hepatobiliary Pancreat Dis Int 1:327–329PubMed
24.
Samuel D, Feray C, Bismuth H (1997) Hepatitis viruses and liver transplantation. J Gastroenterol Hepatol 12:S335–S341PubMed
25.
Samuel D, Muller R, Alexander G, Bismuth H et al (1993) Liver transplantation in European patients with the hepatitis B surface antigen. N Engl J Med 329(25):1842–1847PubMed
26.
Hwang S, Lee SG, Ahn CS et al (2008) Prevention of hepatitis B recurrence after living donor liver transplantation: primary high-dose hepatitis B immunoglobulin monotherapy and rescue antiviral therapy. Liver Transplant 14:770–778
27.
Lu Y, Wang B, Yu L et al (2004) Lamivudine in prevention and treatment of recurrent HBV after liver transplantation. Hepatobiliary Pancreat Dis Int 3:504–507PubMed
28.
Wang ZF, Zhu ZJ, Shen ZY (2005) Advances in prophylaxis and treatment of recurrent hepatitis B after liver transplantation. Hepatobiliary Pancreat Dis Int 4:509–514PubMed
29.
Papatheodordis GV, Sevastianos V, Burroughs AK (2003) Prevention of and treatment for hepatitis B virus infection after liver transplantation in the nucleoside analogues era. Am J Transpl 3:250–258
30.
Mas A (2009) Liver transplantation for hepatitis B virus. Pre-emptive and peri-operative prophylaxis. Dig Liver Dis 41(suppl 2):S191–S194PubMed
31.
Shouval D, Samuel D (2000) Hepatitis B immune globulin to prevent HBV graft reinfection following liver transplantation: a concise review. Hepatology 32:1189–1195PubMed
32.
Van Nunen AB, de Man RA, Heijtink RA et al (2002) Passive immunization of chronic hepatitis B patients on lamivudine therapy: a feasible issue? J Viral Hepatitis 9:221–228
33.
Liu H, Liu YF (2003) Liver transplantation for patients with viral hepatitis. HBPD Int 2:28–31PubMed
34.
Baruch Y, Ben-Porath E, Enat R (1994) Immunoprophylaxis with hepatitis B immunoglobulin after liver transplantation, an economical approach. J Hepatol 20:153PubMed
35.
Hooman N, Rifai K, Hadem J et al (2008) Antibody to hepatitis B surface antigen trough levels and half-lives do not differ after intravenous and intramuscular hepatitis B immunoglobulin administration after liver transplantation. Liver Transplant 14:435–442
36.
Kruger M (2000) European hepatitis B immunoglobulin trials: prevention of recurrent hepatitis B after liver transplantation. Clin Transplant 14(suppl 2):14PubMed
37.
Yao FY, Osorio RW, Roberts JP et al (1999) Intramuscular hepatitis B immune globulin combined with lamivudine for prophylaxis against hepatitis B recurrence after liver transplantation. Liver Transplant Surg 5:491
38.
European Medicines Agency: Core SmPC for human normal immunoglobulin for subcutaneous and intramuscular use. CPMP/BPWG/282/00, London 25 July 2002
39.
Thürmann PA, Szymanski J, Haffner S et al (2006) Pharmacokinetics and safety of a novel anti-HBs-enriched immunoglobulin in healthy volunteers after subcutaneous and intramuscular administration. Eur J Clin Pharmacol 62:511–512PubMed
40.
Lee SK, Park JH, Joh JW et al (2000) Prophylaxis against hepatitis B recurrence following liver transplantation in HBs Ag (+) patients. Transplant Proc 32:2248PubMed
41.
Avolio AW, Nure E, Pompili M et al (2008) Liver transplantation for hepatitis B virus patients: long-term results of three therapeutic approaches. Transplant Proc 40:1961–1964PubMed
42.
Yilmaz N, Shiffman ML, Todd Stravitz R et al (2008) Prophylaxis against recurrence of hepatitis B virus after liver transplantation: a retrospective analysis spanning 20 years. Liver Int 28:72–78PubMed
43.
Gugenheim J, Baldini E, Ouzan D et al (1997) Absence of initial viral replication and long-term high dose immunoglobulin administration improve results of hepatitis B virus recurrence prophylaxis after liver transplantation. Transplant Proc 29:517PubMed
44.
Markowitz JS, Martin P, Conrad AJ et al (1998) Prophylaxis against hepatitis B recurrence following liver transplantation using combination lamivudine and hepatitis B immune globulin. Hepatology 28:585–589PubMed
45.
Ishitani M, McGory R, Dickson R et al (1997) Retransplantation of patients with severe posttransplant hepatitis B in the first allograft. Transplantation 64:410–414PubMed
46.
Adler R, Safadi R, Caraco Y et al (1999) Comparison of immune reactivity and pharmacokinetics of two hepatitis B immune globulins in patients after liver transplantation. Hepatology 29:1299–1305PubMed
47.
Neff GW, Sherman KE (2004) Post-transplant hepatitis: HCV and HBV. Current Hepatitis Reports 3:98–104
48.
Angeli P, Scaglione F (2008) Nephrotoxicity of intravenous immunoglobulin in the setting of liver transplantation or HBV-related cirrhosis: an undervalued topic. Minerva Gastroenterol Dietol 54:259–275PubMed
49.
Habib S, Shaikh OS (2007) Hepatitis B immune globulin. Drug Today 43:379
50.
Golling M, Arnold JC, Rudek B et al (1998) HBV prophylaxis: cost/benefit analysis following liver transplantation for HBV-positive liver cirrhosis. Transplant Proc 30:3316–3317PubMed
51.
Angus PW, Patterson SJ (2008) Liver transplantation for hepatitis B: what is the best hepatitis B immune globulin/antiviral regimen? Liver Transplant 14:S15–S22
52.
Deeney HN, Dusheiko GM (2009) Lamivudine combined with hepatitis B immunoglobulin in for prophylaxis of hepatitis B recurrence after liver transplantation: time for a change? Transpl Int 22:385–386PubMed
53.
Rosenau J, Kreutz TH, Kujawa M et al (2007) HBsAg level at time of liver transplantation determines HBsAg decrease and anti-HBs increase and affects HBV DNA decrease during early immunoglobulin administration. J Hepatol 46:635–644PubMed
54.
Lenci I, Tisone G, Di Paolo D et al (2008) Total and covalently closed circular DNA detection in post liver transplant liver biopsies of HBV positive patients who underwent liver transplantation with undetectable viraemia. Hepatology 44:573A
55.
Dumortier J, Chevallier P, Scoazec JY et al (2003) Combined lamivudine and hepatitis B immunoglobulin for the prevention of hepatitis B recurrence after liver transplantation: long term results. Am J Transplant 3:999–1002PubMed
56.
Faria LC, Gigou M, Roque-Afonso AM et al (2008) Hepatocellular carcinoma is associated with an increased risk of hepatitis B virus recurrence after liver transplantation. Gastroenterology 134:1890–1899PubMed
57.
Zoulim F, Radenne S, Ducert CH (2008) Management of patients with decompensated hepatitis B virus association cirrhosis. Liver Transplant 14:S1–S7
58.
Cooreman MP, Leroux-Roels G, Paulij WP (2001) Vaccine- and hepatitis B immune globulin-induced escape mutations of hepatitis B virus surface antigen. J Biomed Sci 8(3):237–247PubMed
59.
Degertekin B, Han SH, Keeffe EB et al (2010) The NIH HBV-OLT Study Group. Impact of virologic breakthrough and HBIG regimen on hepatitis B recurrence after liver transplant ation. Am J Transplant 10:1823–1833PubMed
60.
Dan YY, Wai CHT, Yeoh KHG et al (2006) Prophylactic strategies for hepatitis B patients undergoing liver transplant: a cost-effectiveness analysis. Liver Transplant 12:736–746
61.
Han SH, Martin P, Edelstein M et al (2003) Conversion from intravenous to intramuscular hepatitis B immune globulin in combination with lamivudine is safe and cost-effective in patients receiving long-term prophylaxis to prevent hepatitis B recurrence after liver transplantation. Liver Transplant 9:182–187
62.
Di Paolo D, Tisone G, Piccolo P et al (2004) Low-dose hepatitis B immunoglobulin given “on demand” in combination with lamivudine: a highly cost-effective approach to prevent recurrent hepatitis B virus infection in the long-term follow-up after liver transplantation. Transplantation 77:1203–1208PubMed
63.
O’Grady JG (1997) Clinical economics review: liver transplantation. Aliment Pharmacol Ther 11:445–451PubMed
64.
Jiao ZY, Jiao Z (2007) Prophylaxis of recurrent hepatitis b in Chinese patients after liver transplantation using lamivudine combined with hepatitis B immune globulin according to the titer of antibody to hepatitis B surface antigen. Transplant Proc 39:1533–1536PubMed
65.
Saab S, Ham MY, Stone MA et al (2009) Decision analysis model for hepatitis B prophylaxis one year after liver transplantation. Liver Transplant 15:413–420
66.
Gane EJ, Angus PW, Strasser S et al (2007) Lamivudine plus low dose hepatitis B immunoglobulin to prevent recurrent hepatitis B following liver transplantation. Gastroenterology 132:931–937PubMed
67.
Jiang L, Jiang LS, Cheng NS et al (2009) Current prophylactic strategies against hepatitis B virus recurrence after liver transplantation. World J Gastroenterol 15:2489–2499PubMed
68.
Dienstag JL, Perrillo RP, Schiff EF et al (1995) A preliminary trial of lamivudine for chronic hepatitis B infection. N Engl J Med 333:1657–1661PubMed
69.
Zoulin F, Trepo C (2000) Is lamivudine effective on precore/core promoter mutants of hepatitis B virus? Hepatology 32:1172–1174
70.
Chen RY, Edwards R, Shaw T et al (2003) Effect of the G1896 A precore mutation on drug sensitivity and replication yield of lamivudine-resistant HBV in vitro. Hepatology 37:27–35PubMed
71.
Fung J, Lai CH-L, Tanaka Y et al (2009) The duration of lamivudine therapy for chronic hepatitis B: cessation vs. continuation of treatment after HBe Ag seroconversion. Am J Gastroenterol 104:1–7
72.
Wai CT, Lim SG, Tan KC (2001) Outcome of lamivudine resistant hepatitis B virus infection in liver transplant recipients in Singapore. Gut 48:581PubMed
73.
Fontana RJ, Keeffe EB, Carey W et al (2002) Effect of lamivudine treatment on survival of 309 North American patients awaiting liver transplantation for chronic hepatitis B. Liver Transplant 8:433–439
74.
Tenney DJ, Pokornowski K, Rose R et al (2008) Entecavir at five years shows long term maintenance of high genetic barrier to hepatitis B virus resistance. Hepatol Int 2:S76–S77
75.
Van Bommel F, Zollner B, Sarrazin C et al (2006) Tenofovir for patients with lamivudine-resistant hepatitis B virus infection and high HBV DNA level during adefovir therapy. Hepatology 44:318–325PubMed
76.
Lai CL, Leung N, Teo EK et al (2005) A 1-year trial of telbivudine, lamivudine and the combination in patients with hepatitis B antigen-positive chronic hepatitis B. Gastroentrology 129:528–536
77.
Angus PW, Patterson SJ, Strasser SI et al (2008) A randomized study of adefovir dipivoxil in place of HBIg in combination with lamivudine as post liver transplantation hepatitis B prophylaxis. Hepatology 48:1460–1466PubMed
78.
Freshwater DA, Dudley T, Cane P et al (2008) Viral persistence after liver transplantation for hepatitis B virus: a cross-sectional study. Transplantation 85:1105–1111PubMed
79.
Schiff E, Lai CL, Hadziyannis S et al (2007) Adefovir dipivoxil for wait-listed and post-liver transplantation patients with lamivudine-resistant hepatitis B: final long-term results. Liver Transplant 13:349
80.
Schiff ER, Lai CL, Hadziyannis S et al (2003) Adefovir dipivoxil therapy for lamivudine-resistant hepatitis B in pre- and post-liver transplantation patients. Hepatology 38:1419PubMed
81.
Chang TT, Gish RG, De Man R et al (2006) A comparison of entecavir and lamivudine for HBeAg-positive chronic hepatitis B. N Engl J Med 354:1001PubMed
82.
Kuo A, Dienstag JL, Chung RT (2004) Tenofovir disoproxil fumarate for the treatment of lamivudine-resistant hepatitis B. Clin Gastroenterol Hepatol 2:266PubMed
83.
Hou J, Yin YK, Xu D et al (2008) Telbivudine versus lamivudine in Chinese patients with chronic hepatitis B: results at 1 year of a randomized, double-blind trial. Hepatology 47:447–454PubMed
84.
Lai CL, Gane E, Liaw YF et al (2007) Telbivudine versus lamivudine in patients with chronic hepatitis B. N Engl J Med 357:2576–2588PubMed
85.
Lee PH, Hu RH, Tsai MK et al (2000) Liver transplantation for patients with hepatitis B: prevention of hepatitis B recurrence by intravenous antihepatitis B immunoglobulin and lamivudine. Transplant Proc 32:2245–2247PubMed
86.
Engler S, Sauer P, Klar E et al (2002) Prophylaxis of hepatitis B recurrence after liver transplantation with lamivudin and hepatitis B immunoglobulin. Transplant Proc 34:2285–2287PubMed
87.
Steinmuller T, Seehofer D, Rayes N et al (2002) Increasing applicability of liver transplantation for patients with hepatitis B-related liver disease. Hepatology 35:1528PubMed
88.
Katze L, Paul M, Guy D et al (2008) Prevention of recurrent hepatitis B virus infection after liver transplantation. HBIg antiviral drugs or both? Systematic review and meta analysis. Hepatology 48:573A
89.
Rizzetto M, Marzano A (2000) Posttransplantation prevention and treatment of recurrent hepatitis B. Liver Transplant 6(Suppl 2):S47–S51
90.
Avery PK, Michaels M (2008) Update on immunizations in solid organ transplant recipients: what clinicians need to know? Am J Transpl 8:9–14
91.
Gunther M, Neuhaus R, Bauer T et al (2006) Immunization with an adjuvant hepatitis B vaccine in liver transplant recipients: antibody decline and booster vaccination with conventional vaccine. Liver Transplant 12:316–319
92.
Di Paolo D, Lenci I, Trinito MO et al (2006) Extended double- dosage HBV vaccination after liver transplantation is ineffective in the absence of lamivudine and prior wash-out of human hepatitis B immunoglobulins. Dig Liver Dis 38:749–754PubMed
93.
Rosenau J, Hooman N, Hadem J et al (2007) Failure of hepatitis B vaccination with conventional HBsAg vaccine in patients with continuous HBIG prophylaxis after liver transplantation. Liver Transplant 13:367–373
94.
Rosenau J, Hooman N, Rifai K et al (2006) Hepatitis B virus immunization with an adjuvant containing vaccine after liver transplantation for hepatitis B-related disease: failure of humoral and cellular immune response. Euro Soc Organ Transplant 19:828–833
95.
Bauer T, Günther M, Bienzle U et al (2007) Vaccination against hepatitis B in liver transplantation recipients: pilot analysis of cellular immune response shows evidence of HBs Ag specific regulatory T cells. Liver Transplant 13:434–442
96.
Sanchez-Fueyo A, Rimola A, Grande L et al (2000) Hepatitis B immunoglobulin discontinuation followed by hepatitis B virus vaccination: a new strategy in the prophylaxis of hepatitis B virus recurrence after liver transplantation. Hepatology 31:496PubMed
97.
Angelico M, Di Paolo D, Trinito MO et al (2002) Failure of a reinforced triple course of hepatitis B vaccination in patients transplanted for HBV-related cirrhosis. Hepatology 35:176PubMed
98.
Cornberg M, Protzer U, Dollinger MM et al (2007) Prophylaxis, diagnosis and therapy of hepatitis-B-virus-(HBV-) infection: upgrade of the guideline, AWMF-Register 021/011. Z Gastroenterol 45:525–574PubMed
99.
Cornberg M, Protzer U, Dollinger MM et al (2008) The German guideline for the management of hepatitis B virus infection. J Viral Hepatitis 15:1–20
100.
Bienzle U, Gunther M, Neuhaus R et al (2003) Immunization with an adjuvant hepatitis B vaccine after liver transplantation for hepatitis B-related disease. Hepatology 38:811–819PubMed
101.
Chang SH, Suh KS, Yi NJ et al (2003) Active immunization against de novo hepatitis B virus infection in pediatric patients after liver transplantation. Hepatology 37:1329PubMed
102.
Serrano B, Bayas JM, Bruni L et al (2007) Solid organ transplantation and response to vaccination. Vaccine 25:7331PubMed
103.
Loinaz C, de Juanes JR, Gonzalez EM et al (1997) Hepatitis B vaccination results in 140 liver transplant recipients. Hepatogastroenterology 44:235PubMed
104.
Dahmen U, Dirsch O, Li J et al (2004) Adoptive transfer of immunity: a new strategy to interfere with severe hepatitis virus reinfection after woodchuck liver transplantation. Transplantation 77:965–972PubMed
105.
Shouval D (2007) Adoptive transfer of immunity to HBV in liver transplant patients: a step forward toward the proof of concept for therapeutic vaccination or a transient immunologic phenomenon? Liver Transplant 13:14–17
106.
Luo Y, Lo CM, Cheung CK et al (2007) Identification of hepatitis B virus-specific lymphocytes in human liver grafts from HBV-immune donors. Liver Transplant 13:71–79
107.
Lo CM, Lau GK, Chan SC et al (2007) Efficacy of a pre-S containing vaccine in patients receiving lamivudine prophylaxis after liver transplantation for chronic hepatitis B. Am J Transplant 7:434–439PubMed
108.
Vandepapeliere P, Lau GK, Leroux-Roels G et al (2007) Therapeutic vaccination of chronic hepatitis B patients with virus suppression by antiviral therapy: a randomized, controlled study of co-administration of HBsAg/AS02 candidate vaccine and lamivudine. Vaccine 25:8585–8597PubMed
109.
Schumann A, Fiedler M, Dahmen U et al (2007) Cellular and humoral immune response to a third generation hepatitis B vaccine. J Viral Hepat 14:592–598PubMed
110.
Protzer-Knolle U, Naumann U, Bartenschlager R et al (1998) Hepatitis B virus with antigenically altered hepatitis B surface antigen is selected by high-dose hepatitis B immune globulin after liver transplantation. Hepatology 27:254–263PubMed
111.
Samuel D, Bismuth A, Serres C et al (1991) HBV infection after liver transplantation in HBsAg positive patients: experience with long-term immunoprophylaxis. Transplant Proc 23:1492–1494PubMed
112.
Buti M, Mass A, Prieto M et al (2000) Rabdomized clinical trial of lamivudine vs. lamivudine+hepatitis B gammaglobulin in the prevention of HBV recurrence after liver transplant-preliminary results. Hepatology 32:217A
113.
Roque-Afonso AM, Feray C, Samuel D et al (2002) Antibodies to hepatitis B surface antigen prevent viral reactivation in recipients of liver grafts from anti-HBC positive donors. Gut 50:95–99PubMed
114.
Roche B, Samuel D, Roque AM et al (1999) J Hepatol 30(Suppl 1):80
115.
Yoshida EM, Erb SR, Partovi N et al (1999) Liver transplantation for chronic hepatitis B infection with the use of combination lamivudine and low dose hepatitis B immune globulin. Liver Transplant Surg 5:520–525
116.
Dodson SF, Bonham CA, Geller DA et al (1999) Prevention of de novo hepatitis B infection in recipients of hepatic allografts from anti-HBc positive donors. Transplantation 68:1058–1061PubMed
117.
Angus PW, McCaughen GW, Gane EJ et al (2000) Combination low-dose hepatitis B immune globulin and lamivudine therapy provides effective prophylaxis against post transplantation hepatitis B. Liver Transplant 6:429–433
118.
Han SH, Ofman J, Holt C et al (2000) An efficacy and cost effectiveness analysis of combination hepatitis B immune globulin and lamivudine to prevent recurrent hepatitis B after orthotopic liver transplantation compared with hepatitis B immune globulin monotherapy. Liver Transplant 6:741
119.
Anselmo DM, Ghobrial RM, Jung LC et al (2002) New era of liver transplantation for hepatitis B: a 17 year single-center experience. Ann Surg 235:611–619PubMed
120.
Rosenau J, Bahr MJ, Tillmann HL et al (2001) Lamivudine and low dose hepatitis B immune globulin for prophylaxis of hepatitis B reinfection after liver transplantation possible role to transplantation as a risk factor for reinfection. J Hepatol 34:895–902PubMed
121.
Marzano A, Salizzoni M, Debernardi-Venon W et al (2001) Prevention of hepatitis B virus recurrence after liver transplantation in cirrhotic patients treated with lamivudine and passive immunoprophylaxis. J Hepatol 34:903–910PubMed
122.
Seehofer D, Rayes N, Steinmüller T et al (2002) Combination prophylaxis with Hepatitis B immunoglobulin and lamivudine after liver transplantation minimizes HBV recurrence rates unless evolution of pretransplant lamivudine resistance. Z Gastroenterol 40:795–799PubMed
123.
Lee KW, Lee DS, Lee HH et al (2004) Prevention of de novo hepatitis B infection from HbcAb-positive donors in living donor liver transplantation. Transplant Proc 36:2311–2312PubMed
124.
Ferretti G, Merli M, Ginanni Corradini S et al (2004) Low-dose intramuscular hepatitis B immune globulin and lamivudine for long-term prophylaxis of hepatitis B recurrence after liver transplantation. Transplant Proc 36:535–538PubMed
125.
Neff GW, O’Brien CB, Nery J et al (2004) Outcomes in liver transplant recipients with hepatitis B virus: resistance and recurrence patterns from a large transplant center over the last decade. Liver Transplant 10:1372–1378
126.
Dickson RC, Terrault NA, Ishitani M et al (2006) Protective antibody levels and dose requirements for IV 5% Nabi hepatitis B immune globulin combined with lamivudine in liver transplantation for hepatitis B-induced end stage liver disease. Liver Transplant 12:124–133
127.
Yan ML, Yan LN, Li B et al (2006) Intramuscular hepatitis B immune globulin combined with lamivudine in prevention of hepatitis B recurrence after liver transplantation. Hepatobiliary Pancreat Dis Int 5:360–363PubMed
128.
Zheng S, Chen Y, Liang T et al (2006) Prevention of hepatitis B recurrence after liver transplantation using lamivudine or lamivudine combined with hepatitis B immunoglobulin prophylaxis. Liver Transplant 12:253–258
129.
Wong SN, Chu CJ, Wai CT et al (2007) Low risk of hepatitis B virus recurrence after withdrawal of long term hepatitis B immunoglobulin in patients receiving maintenance nucleoside analogue therapy. Liver Transplant 13:374–381
130.
Akyildiz M, Karasu Z, Zeytunlu M et al (2007) Adefovir dipivoxil therapy in liver transplant recipients for recurrence of hepatitis B virus infection despite lamivudine plus hepatitis B immunoglobulin prophylaxis. J Gastroenterol Hepatol 22:2130–2134PubMed
131.
Iacob S, Hrehoret D, Matei E et al (2008) Costs and efficacy of “on demand” low-dose immunoprophylaxis in HBV transplanted patients: experience in the Romanian program of liver transplantation. J Gastrointestin Liver Dis 17:383–388PubMed
132.
Woo HY, Choi JY, Jang JW et al (2008) Role of long-term lamivudine treatment of hepatitis B virus recurrence after liver transplantation. J Med Virol 80:1891–1899PubMed
Metadaten
Titel
The role of HBIg as hepatitis B reinfection prophylaxis following liver transplantation
verfasst von
Arianeb Mehrabi
Majid Esmaeilzadeh
Hamidreza Fonouni
Mohammadreza Hafezi
Nuh N. Rahbari
Mohammad Golriz
Ali Majlesara
Morva Tahmasbi Rad
Mahmoud Sadeghi
Jan Schmidt
Tom M. Ganten
Publikationsdatum
01.06.2012
Verlag
Springer-Verlag
Erschienen in
Langenbeck's Archives of Surgery / Ausgabe 5/2012
Print ISSN: 1435-2443
Elektronische ISSN: 1435-2451
DOI
https://doi.org/10.1007/s00423-011-0795-6

Weitere Artikel der Ausgabe 5/2012

Langenbeck's Archives of Surgery 5/2012 Zur Ausgabe

Abstracts

5th biennual congress of the European Society of Endocrine Surgeons (ESES) Gothenburg Sweden, May 24–26, 2012

Original Article

Analysis of sentinel lymph node biopsy results in colon cancer in regard of the anthropometric features of the population and body composition assessment formulas

Rapid Communication

The safety of energy-based devices in open thyroidectomy: a prospective, randomised study comparing the LigaSure™ (LF1212) and the Harmonic® FOCUS

Original Article

Estimate or calculate? How surgeons rate volumes and surfaces

Rapid Communication

Prognostic factors in differentiated thyroid cancer—a 20-year surgical outcome study

Original Article

Can we direct organ allocation based on predicted outcome? Hepatocellular carcinoma outside of UCSF criteria or retransplant?

Neu im Fachgebiet Chirurgie

23.04.2024 | Ablationstherapie | Nachrichten

Wie erfolgreich ist eine Re-Ablation nach Rezidiv?

23.04.2024 | Appendizitis | Nachrichten

Hinter dieser Appendizitis steckte ein Erreger

23.04.2024 | Operationsvorbereitung | Nachrichten

Mehr Schaden als Nutzen durch präoperatives Aussetzen von GLP-1-Agonisten?

19.04.2024 | EAU 2024 | Kongressbericht | Nachrichten

Ureterstriktur: Innovative OP-Technik bewährt sich
weitere anzeigen

Update Chirurgie

Bestellen Sie unseren Fach-Newsletter und bleiben Sie gut informiert.

Newsletter bestellen

Aktuelle BDC Leitlinien-Webinare

S3-Leitlinie „Diagnostik und Therapie des Karpaltunnelsyndroms“

Karpaltunnelsyndrom BDC Leitlinien Webinare
CME: 2 Punkte

Das Karpaltunnelsyndrom ist die häufigste Kompressionsneuropathie peripherer Nerven. Obwohl die Anamnese mit dem nächtlichen Einschlafen der Hand (Brachialgia parästhetica nocturna) sehr typisch ist, ist eine klinisch-neurologische Untersuchung und Elektroneurografie in manchen Fällen auch eine Neurosonografie erforderlich. Im Anfangsstadium sind konservative Maßnahmen (Handgelenksschiene, Ergotherapie) empfehlenswert. Bei nicht Ansprechen der konservativen Therapie oder Auftreten von neurologischen Ausfällen ist eine Dekompression des N. medianus am Karpaltunnel indiziert.

Prof. Dr. med. Gregor Antoniadis
Berufsverband der Deutschen Chirurgie e.V.

S2e-Leitlinie „Distale Radiusfraktur“

Radiusfraktur BDC Leitlinien Webinare
CME: 2 Punkte

Das Webinar beschäftigt sich mit Fragen und Antworten zu Diagnostik und Klassifikation sowie Möglichkeiten des Ausschlusses von Zusatzverletzungen. Die Referenten erläutern, welche Frakturen konservativ behandelt werden können und wie. Das Webinar beantwortet die Frage nach aktuellen operativen Therapiekonzepten: Welcher Zugang, welches Osteosynthesematerial? Auf was muss bei der Nachbehandlung der distalen Radiusfraktur geachtet werden?

PD Dr. med. Oliver Pieske
Dr. med. Benjamin Meyknecht
Berufsverband der Deutschen Chirurgie e.V.

S1-Leitlinie „Empfehlungen zur Therapie der akuten Appendizitis bei Erwachsenen“

Appendizitis BDC Leitlinien Webinare
CME: 2 Punkte

Inhalte des Webinars zur S1-Leitlinie „Empfehlungen zur Therapie der akuten Appendizitis bei Erwachsenen“ sind die Darstellung des Projektes und des Erstellungswegs zur S1-Leitlinie, die Erläuterung der klinischen Relevanz der Klassifikation EAES 2015, die wissenschaftliche Begründung der wichtigsten Empfehlungen und die Darstellung stadiengerechter Therapieoptionen.

Dr. med. Mihailo Andric
Berufsverband der Deutschen Chirurgie e.V.